DNA vaccines: a key for inducing long-term cellular immunity.
about
Cytokine-associated neutrophil extracellular traps and antinuclear antibodies in Plasmodium falciparum infected children under six years of ageBiodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccinesAspects of T Cell-Mediated Immunity Induced in Mice by a DNA Vaccine Based on the Dengue-NS1 Antigen after Challenge by the Intracerebral RouteMolecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccinationNanodelivery: An Emerging Avenue for Nutraceuticals and Drug Delivery.Identification and molecular characterization of a gene encoding a protective Leishmania amazonensis Trp-Asp (WD) protein.Protective immunity induced by DNA-library immunization against an intracellular bacterial infection.Immunization with a DNA vaccine encoding Toxoplasma gondii Superoxide dismutase (TgSOD) induces partial immune protection against acute toxoplasmosis in BALB/c mice.Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice.Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses.Leishmaniasis: current status of vaccine developmentInduction of immune response in BALB/c mice with a DNA vaccine encoding bacterioferritin or P39 of Brucella spp.Deficiency in B7-H1 (PD-L1)/PD-1 coinhibition triggers pancreatic beta-cell destruction by insulin-specific, murine CD8 T-cells.A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response.Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c miceVaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infectionLow-dose plasmid DNA treatment increases plasma vasopressin and regulates blood pressure in experimental endotoxemia.A GRA1 DNA vaccine primes cytolytic CD8(+) T cells to control acute Toxoplasma gondii infectionSafety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteersVaccination with lentiviral vector expressing the nfa1 gene confers a protective immune response to mice infected with Naegleria fowleri.Molecular biological applications in the diagnosis and control of leishmaniasis and parasite identification.DNA vaccine using Mycobacterium bovis Ag85B antigen induces partial protection against experimental infection in BALB/c mice.The future of vaccination as a treatment strategy in dermatological diseases.Analysis of pulpal reactions to restorative procedures, materials, pulp capping, and future therapies.Transfected Plasmodium knowlesi produces bioactive host gamma interferon: a new perspective for modulating immune responses to malaria parasites.Development of a leishmaniasis vaccine: the importance of MPL.Vaccines in leishmaniasis: advances in the last five years.Leishmania mexicana Gp63 cDNA Using Gene Gun Induced Higher Immunity to L. mexicana Infection Compared to Soluble Leishmania Antigen in BALB/CDeveloping DNA vaccines that call to dendritic cells.Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding Brucella melitensis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting.A candidate DNA vaccine elicits HCV specific humoral and cellular immune responses.Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against LeishmaniaAntigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous LeishmaniasisDNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice.The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells.Development of Leishmania vaccines: predicting the future from past and present experience.Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization.Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells.Immunogenicity of RSV F DNA Vaccine in BALB/c Mice.
P2860
Q21034151-DFA7D3EC-3F38-4FE0-8641-F06326E0EDFEQ26861389-1CEB2D4A-0BAC-48C6-9F5E-94D9EC0FAF51Q27321668-B697CF21-752A-4EAA-A31B-1F7C7EBE83C4Q28236770-50E47C19-DD81-4BBD-A62C-5C34C660E13DQ30252169-B70CF4E3-12D5-425C-AE92-95754DA7332DQ33200061-8AE2628A-8938-4B85-A0EB-50125DA225B2Q33203877-73D4565C-A6BB-4FCA-98C6-B8AC3879B6AAQ33776827-F339142A-08CF-4722-8A95-C365AEC31D10Q33818084-BBE3F66C-1F5E-468E-A843-3FE53B322885Q33849973-8B928A97-1F45-46B7-A7E0-64DAD796F706Q33941719-C295897E-8BBC-4BF6-B22A-9CE0185E6536Q34009351-D53FA487-7AD3-4920-9A22-D11C07AC137EQ34024395-73F9F8BC-EC61-4F85-9DC1-9077AE31270CQ34033400-1DAC592A-BB83-40F2-9D4F-1FE597D17F63Q34123352-BACC2F56-7076-4F87-9B76-FD9A12606869Q34194709-DA8DF8F1-80A6-42BD-AC39-6425F4A8326BQ34471220-D7F39084-51BF-496C-9342-FF990EAD62FFQ34525371-C2F04073-4A7A-4109-9789-02F0759971C6Q34589611-20505B37-5461-4A23-ADC3-D7522D41F635Q34724869-1B881A34-FCC8-449E-B857-BC4085112181Q34776421-87692324-2C31-4CD1-AD9C-88546F14CB32Q34975023-258927A3-4B43-4520-81AA-A5702E30BDE6Q35015879-9A9E32C1-798C-4EB7-AB61-61D6205B9F2AQ35033477-46A29839-8696-4F11-BDFE-E75BCF56A1D0Q35165305-57476D64-B5DD-4B88-9C5A-6E97699065C0Q35192190-0CB3B324-B808-41BB-9CEE-880A6DF5D5F4Q35623310-744C54F2-1489-4629-B633-92D96F919D4FQ35758166-4A14DE69-5E3A-48E5-A056-C9012354EB41Q35936512-4B446EA0-BE83-41D6-AA6D-C0FA1E53F283Q35946874-6703D6EC-6F40-45EA-92AE-59C842D293EEQ36065682-F831C486-B6C8-469D-B61B-82F494087419Q36251325-EB648665-1B4E-4AF5-9ED1-D30B5E4FBAFCQ36327377-091A8CB9-F82B-4E48-861D-CBB45FE15CD9Q36376098-908C878B-A2EE-497F-A3FF-FF6EA52F92F2Q36445502-6F0D2D90-DB42-4BCC-A5E5-CF7A02AF045EQ36489528-8EA00EC3-FE4F-4DDF-9EE9-DAB72A67D20DQ36700453-5A8B3524-AF06-4327-9553-818867E41476Q36819089-06C49F28-4476-4549-84EE-4A1B0096401AQ36851026-6F89F04B-51C0-4557-828F-6EC8597575D1Q37263840-9CEE78DB-E4A6-4EC2-9BF8-42F376E58E00
P2860
DNA vaccines: a key for inducing long-term cellular immunity.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
DNA vaccines: a key for inducing long-term cellular immunity.
@ast
DNA vaccines: a key for inducing long-term cellular immunity.
@en
type
label
DNA vaccines: a key for inducing long-term cellular immunity.
@ast
DNA vaccines: a key for inducing long-term cellular immunity.
@en
prefLabel
DNA vaccines: a key for inducing long-term cellular immunity.
@ast
DNA vaccines: a key for inducing long-term cellular immunity.
@en
P2093
P1476
DNA vaccines: a key for inducing long-term cellular immunity.
@en
P2093
P304
P356
10.1016/S0952-7915(00)00118-7
P577
2000-08-01T00:00:00Z